Immix Biopharma, Inc. (IMMX): R&D Expense
$16.26M
Year ended 2025-12-31
$21.62M
Trailing 12 months to 2026-06-30
+57.1%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $16.26M | +44.0% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $11.29M | +29.3% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $8.74M | +108.2% | 2025-03-25, From 2023-01-01 |
| 2022-12-31 | $4.20M | n/m | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $126.5K | -49.0% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $248.1K | n/a | 2022-03-28, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | 2025-12-31 | $16.26M | +44.0% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $0 | -100.0% |
| Tenax Therapeutics, Inc. (TENX) | 2025-12-31 | $32.67M | +157.1% |
| Celularity Inc (CELU) | 2025-12-31 | $15.03M | -13.6% |
| Karyopharm Therapeutics Inc. (KPTI) | 2025-12-31 | $125.62M | -12.3% |
| Citius Oncology, Inc. (CTOR) | 2025-09-30 | $6.42M | +30.3% |
| iBio, Inc. (IBIO) | 2026-06-30 | $19.64M | +136.3% |
| Minerva Neurosciences, Inc. (NERV) | 2025-12-31 | $5.76M | -51.6% |
| Rezolute, Inc. (RZLT) | 2026-06-30 | $53.80M | -12.6% |
Compare IMMX, AYTU, TENX, CELU side by side · Screen every company in Pharmaceutical Preparations ↗